Fremman Capital is set to acquire Amethyst Healthcare Group, a prominent European cancer care provider, from its founding shareholders and The Rohatyn Group (TRG). Established in 2010 by Ludovic Robert and the Goldenberg family, Amethyst operates 19 cancer treatment centers across several European countries, including France, Poland, Romania, the UK, Italy, and Austria. The organization primarily focuses on radiotherapy, serving over 50,000 patients annually with a team of over 500 professionals and a network of around 40 linear accelerators.

Edward Chandler, founding partner at Fremman Capital, expressed that Amethyst aligns well with their strategy of supporting leading providers of essential services. The firm plans to leverage its extensive healthcare experience and international presence to accelerate Amethyst’s growth and establish it as a European leader in radiotherapy. The radiotherapy market is expected to see significant growth due to demographic trends and its recognition as a cost-effective, non-invasive cancer treatment option.

TRG initially invested in Amethyst in 2019, recognizing the company's potential to meet the increasing demand for cancer care in Europe. Their investment strategy focused on expanding the company through the acquisition of clinics, developing new centers, and forming partnerships with hospitals. Colin Clark, partner and head of Europe at TRG, noted that during their ownership, Amethyst experienced substantial growth, evolving into a significant player in the European market.

When TRG invested, Amethyst operated nine centers across five countries, treating over 10,000 patients annually. Since then, the company has expanded its operations significantly. In 2020, Amethyst entered the Austrian market and expanded into the UK by acquiring Medical Equipment Solutions Limited, which specializes in intracranial radiation treatments. The following years saw further expansion, with new centers opening in France, Romania, and Italy.

In 2024, Amethyst secured a €300 million financing agreement with Ares Management Corporation to support its ambitious growth plans. This funding will facilitate investments in advanced radiotherapy technologies and the establishment of new treatment centers across Europe, enhancing both capacity and strategic acquisitions.

Fremman Capital's acquisition of Amethyst marks a significant step in the evolution of cancer care in Europe, positioning the company for continued growth and innovation in the radiotherapy sector.